1. Home
  2. CRDF vs LPAA Comparison

CRDF vs LPAA Comparison

Compare CRDF & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDF
  • LPAA
  • Stock Information
  • Founded
  • CRDF 1999
  • LPAA 2024
  • Country
  • CRDF United States
  • LPAA United States
  • Employees
  • CRDF N/A
  • LPAA N/A
  • Industry
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • LPAA
  • Sector
  • CRDF Health Care
  • LPAA
  • Exchange
  • CRDF Nasdaq
  • LPAA Nasdaq
  • Market Cap
  • CRDF 288.7M
  • LPAA 290.4M
  • IPO Year
  • CRDF N/A
  • LPAA 2024
  • Fundamental
  • Price
  • CRDF $3.83
  • LPAA $10.20
  • Analyst Decision
  • CRDF Strong Buy
  • LPAA
  • Analyst Count
  • CRDF 4
  • LPAA 0
  • Target Price
  • CRDF $12.00
  • LPAA N/A
  • AVG Volume (30 Days)
  • CRDF 1.1M
  • LPAA 46.5K
  • Earning Date
  • CRDF 05-01-2025
  • LPAA 01-01-0001
  • Dividend Yield
  • CRDF N/A
  • LPAA N/A
  • EPS Growth
  • CRDF N/A
  • LPAA N/A
  • EPS
  • CRDF N/A
  • LPAA N/A
  • Revenue
  • CRDF $683,000.00
  • LPAA N/A
  • Revenue This Year
  • CRDF N/A
  • LPAA N/A
  • Revenue Next Year
  • CRDF N/A
  • LPAA N/A
  • P/E Ratio
  • CRDF N/A
  • LPAA N/A
  • Revenue Growth
  • CRDF 39.96
  • LPAA N/A
  • 52 Week Low
  • CRDF $2.01
  • LPAA $9.66
  • 52 Week High
  • CRDF $6.42
  • LPAA $10.20
  • Technical
  • Relative Strength Index (RSI)
  • CRDF 43.91
  • LPAA N/A
  • Support Level
  • CRDF $3.52
  • LPAA N/A
  • Resistance Level
  • CRDF $4.42
  • LPAA N/A
  • Average True Range (ATR)
  • CRDF 0.29
  • LPAA 0.00
  • MACD
  • CRDF -0.04
  • LPAA 0.00
  • Stochastic Oscillator
  • CRDF 18.89
  • LPAA 0.00

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

About LPAA Launch One Acquisition Corp. Class A Ordinary shares

Launch One Acquisition Corp is a blank check company.

Share on Social Networks: